These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 20431558)

  • 21. Do companion diagnostics make economic sense for drug developers?
    Agarwal A
    N Biotechnol; 2012 Sep; 29(6):695-708. PubMed ID: 22575210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The biggest challenges currently facing companion diagnostic advancement.
    Halim AB
    Expert Rev Mol Diagn; 2014 Jan; 14(1):27-35. PubMed ID: 24308333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic testing in cancer therapeutics.
    Ezzeldin HH; Diasio RB
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4137-41. PubMed ID: 16857783
    [No Abstract]   [Full Text] [Related]  

  • 24. Combat against cancer with science and medicine.
    Chow LW; Toi M
    Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S3-4. PubMed ID: 20374027
    [No Abstract]   [Full Text] [Related]  

  • 25. Update on pharmacogenetics in cancer chemotherapy.
    Innocenti F; Ratain MJ
    Eur J Cancer; 2002 Mar; 38(5):639-44. PubMed ID: 11916544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From the lab to the clinic: integration of pharmacogenics into clinical development.
    Hoban CJ
    Pharmacogenomics; 2002 Jul; 3(4):429-36. PubMed ID: 12164766
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacogenomics. Cancer sharpshooters rely on DNA tests for a better aim.
    Couzin J
    Science; 2004 Aug; 305(5688):1222-3. PubMed ID: 15333809
    [No Abstract]   [Full Text] [Related]  

  • 28. Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs.
    Tibau A; Díez-González L; Navarro B; Galán-Moya EM; Templeton AJ; Seruga B; Pandiella A; Amir E; Ocana A
    Mol Diagn Ther; 2017 Jun; 21(3):337-343. PubMed ID: 28247182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
    Wellmann R; Borden BA; Danahey K; Nanda R; Polite BN; Stadler WM; Ratain MJ; O'Donnell PH
    Cancer; 2018 Jul; 124(14):3052-3065. PubMed ID: 29742281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetics of cytotoxic drugs.
    Daly AK; Hall AG
    Expert Rev Anticancer Ther; 2001 Aug; 1(2):301-8. PubMed ID: 12113035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. iGMDR: Integrated Pharmacogenetic Resource Guide to Cancer Therapy and Research.
    Chen X; Guo Y; Chen X
    Genomics Proteomics Bioinformatics; 2020 Apr; 18(2):150-160. PubMed ID: 32916316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targets for treatment success.
    Simon R
    Nat Clin Pract Oncol; 2006 Jan; 3(1):1. PubMed ID: 16407857
    [No Abstract]   [Full Text] [Related]  

  • 33. Gene expression profiling of treatment resistance: hype or hope for therapeutic target identification.
    Helleman J; Jansen MP; Berns EM
    Int J Gynecol Cancer; 2006; 16 Suppl 2():538-42. PubMed ID: 17010068
    [No Abstract]   [Full Text] [Related]  

  • 34. Genomic medicines for oncology: early lessons.
    Simons JW
    J Med Assoc Ga; 2003; 92(1):35-8. PubMed ID: 12743904
    [No Abstract]   [Full Text] [Related]  

  • 35. Ubiquitin Drug Discovery & Diagnostics 2009 - First Annual Conference.
    Marblestone JG
    IDrugs; 2009 Dec; 12(12):750-3. PubMed ID: 19943215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrating molecular diagnostics into anticancer drug discovery.
    Peták I; Schwab R; Orfi L; Kopper L; Kéri G
    Nat Rev Drug Discov; 2010 Jul; 9(7):523-35. PubMed ID: 20531274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The potential of circulating nucleic acids as components of companion diagnostics for predicting and monitoring chemotherapy response.
    Schwarzenbach H
    Expert Rev Mol Diagn; 2015 Feb; 15(2):267-75. PubMed ID: 25382372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Made-to-order medicine.
    Begley S
    Newsweek; 2001 Jun; 137(26):64-6, 68-9. PubMed ID: 11436376
    [No Abstract]   [Full Text] [Related]  

  • 39. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses.
    Ocana A; Ethier JL; Díez-González L; Corrales-Sánchez V; Srikanthan A; Gascón-Escribano MJ; Templeton AJ; Vera-Badillo F; Seruga B; Niraula S; Pandiella A; Amir E
    Oncotarget; 2015 Nov; 6(37):39538-49. PubMed ID: 26446908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential Reuse of Oncology Drugs in the Treatment of Rare Diseases.
    Liu Z; Fang H; Slikker W; Tong W
    Trends Pharmacol Sci; 2016 Oct; 37(10):843-857. PubMed ID: 27461952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.